Search Results

You are looking at 1 - 10 of 121 items for :

  • "allogeneic stem cell transplantation" x
Clear All
Full access

James M. Cleary, Scott Rodig, Paul M. Barr, Atul B. Shinagare, Jeffrey W. Clark, Geoffrey I. Shapiro and Philippe Armand

achieve remission, allogeneic stem cell transplant is a potentially curative option. 3 In a retrospective analyses of 27 patients with anaplastic large cell lymphoma who underwent an allogeneic stem cell transplant, Le Gouill et al 4 found a 55% 5-year

Full access

Vijaya Raj Bhatt, Mojtaba Akhtari, R. Gregory Bociek, Jennifer N. Sanmann, Ji Yuan, Bhavana J. Dave, Warren G. Sanger, Anne Kessinger and James O. Armitage

to the recommendation of allogeneic stem cell transplantation (allo-SCT) whenever possible, 6 but its prognostic significance and the optimal treatment of Ph + -AML are not clear. With the current treatment options, the outcome is dismal (with a

Full access

Jeffrey E. Lancet and Sergio Giralt

or older . Biol Blood Marrow Transplant 2005 ; 11 : 764 – 772 . 64. Tauro S Craddock C Peggs K . Allogeneic stem cell transplantation using a reduced intensity conditioning regimen has the capacity to produce durable remissions and ling

Full access

Michael Angarone and Michael G. Ison

; 2002 . 3. Ng AP Worth L Chen L . Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation . Haematologica 2005 ; 90 : 1672 – 1679 . 4. Thursky KA

Full access

Leona Holmberg and David G. Maloney

similar long-term outcomes for patients treated with each approach. 35 Table 3 Selected Trials of Allogeneic Stem Cell Transplant for Hodgkin Lymphoma Reduced-Intensity and Nonmyeloablative AlloHCT The past 10 to 15 years have seen a

Full access

Jean-Luc Harousseau and Philippe Moreau

responding to donor lymphocyte infusions following nonmyeloablative stem cell transplantation in multiple myeloma . Blood 2006 ; 107 : 3415 – 3416 . 44. Kroger N Zabelina T Ayuk F . Bortezomib after dose-reduced allogeneic stem cell

Full access

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler

patients who underwent a transplant in advanced phase. Figure 2 Survival probability after allogeneic stem cell transplant. Tick marks indicate last observation of living patients. From Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic

Full access

William I. Bensinger

-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions . Br J Haematol 2003 ; 123 : 309 – 322 . 11 Attal M Harousseau JL Stoppa AM . High

Full access

Edward A. Faber Jr. and Julie M. Vose

cytoxan/fludarabine/high-dose rituximab regimen followed by an allogeneic stem cell transplant in patients with relapsed follicular lymphoma to try to reproduce the M. D. Anderson results, because it was a single-center study with potential selection bias

Full access

Patricia Thompson and Mayer Fishman

– 758 . 60 Ueno NT Cheng YC Rondon G . Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid